Formulary guidance and transparency from P&T to point of care


Reality Check on Macular Edema

Market access for macular edema treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 37% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In August 2019, the FDA granted approval to Eylea (aflibercept) as a prefilled syringe. It remains available in the original single-dose vial for which it was approved in November 2011. The Regeneron Pharmaceuticals, Inc. product is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy
  • Key Findings: Multiple drugs are in late-stage clinical trials for macular edema, including biosimilar versions of Lucentis. Trials also are evaluating therapies that target different pathways and are effective for a longer duration than the current treatments

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.